AnaBioTec is specialized in analytical method development and validation as well as stability and release studies of drug substances and products according to GMP guidelines.
AnaBioTec, focusing on Small molecules; Biologics & Biosimilars; and Cell & Gene Therapy solutions, is presently investing in knowledge and expertise to enable quality analytical services for therapeutic oligonucleotides. For this a state-of-the-art high resolution mass spectrometer will be operational at the end of 2020.
AnaBioTec is also investing in building up knowledge, which is reflected by a recent paper entitled: “Current State of Oligonucleotide Characterization Using Liquid Chromatography−Mass Spectrometry: Insight into Critical Issues”, co-authored by William D. van Dongen of Anabiotech, published in J. Am. Soc. Mass Spectrom. 2020, 31, 1775−1782, https://pubs.acs.org/doi/10.1021/jasms.0c00179.